HIV Resistance Publications - May to July/August 2009
Title / Author / Journal / Volume / IssueAbstracts Presented at the XVIII International HIV Drug Resistance Workshop / June 2009, Florida
Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor. / HoSK / AIDS - Epub ahead of print
The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy. / Ferns RB / AIDS - Epub ahead of print
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial / Soulié, Cathia / AIDS - July 2009 / 23 / 12
Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine in clinical samples / Kagan, Ron M / AIDS - July 2009 / 23 / 12
The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection / Yerly, Sabine / AIDS - July 2009 / 23 / 11
Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing / Archer, John / AIDS - June 2009 / 23 / 10
The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy / Hosseinipour, Mina C / AIDS - June 2009 / 23 / 9
Antiretroviral medication adherence and the development of class-specific antiretroviral resistance / Gardner, Edward M / AIDS - June 2009 / 23 / 9
Increased mutations in Env and Pol suggest greater HIV-1 replication in sputum-derived viruses compared with blood-derived viruses / Wagner, Thor A / AIDS - May 2009 / 23 / 8
Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance / McIntyre, James A / AIDS - April 2009 / 23 / 7
Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda / Eshleman, Susan H / AIDS - April 2009 / 23 / 7
Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1 / The TEmAA ANRS 12109 Study group / AIDS - April 2009 / 23 / 7
Comparison of Laboratory Methods for Analysis of Non-nucleoside Reverse Transcriptase Inhibitor Resistance in Ugandan Infants / Jessica D. Church / Aids Research and Human Retroviruses - July 2009 / 25 / 7
Pol Bootscanning Analysis of HIV Type 1 Can Exhibit Unexpected Recombinations / Anne-Cécile Jeannot / Aids Research and Human Retroviruses - July 2009 / 25 / 7
Analysis of HIV Type 1 gp41 and Enfuvirtide Susceptibility among Men in the United States Who Were HIV Infected Prior to Availability of HIV Entry Inhibitors / Sarah E. Hudelson / Aids Research and Human Retroviruses - July 2009 / 25 / 7
Comparison of HIV Type 1 Sequences from Plasma, Cell-Free Breast Milk, and Cell-Associated Breast Milk Viral Populations in Treated and Untreated Women in Mozambique / Mauro Andreotti / Aids Research and Human Retroviruses - July 2009 / 25 / 7
Characterization of Genetically Diverse HIV Type 1 from a London Cohort: Near Full-Length Genomic Analysis of a Subtype H Strain / Vera Holzmayer / Aids Research and Human Retroviruses - July 2009 / 25 / 7
Modulation of K65R Selection by Zidovudine Inclusion: Analysis of HIV Resistance Selection in Subjects with Virologic Failure Receiving Once-Daily Abacavir/Lamivudine/Zidovudine and Tenofovir DF (Study COL40263) / Lisa Ross / Aids Research and Human Retroviruses - July 2009 / 25 / 7
In Utero HIV Infection Is Associated with an Increased Risk of Nevirapine Resistance in Ugandan Infants Who Were Exposed to Perinatal Single Dose Nevirapine / Jessica D. Church / Aids Research and Human Retroviruses - July 2009 / 25 / 7
Current HIV Type 1 Molecular Epidemiology Profile and Identification of Unique Recombinant Forms in Jakarta, Indonesia / Ivo N. Sahbandar / Aids Research and Human Retroviruses - July 2009 / 25 / 7
Near Full-Length Genome Characterization of an HIV-1 CRF01_AE Strain in Jiangsu, China: Evidence of Two Independent Introductions from Fujian / Dongmei Guo / Aids Research and Human Retroviruses - June 2009 / 25 / 6
Phylogenetic Analysis of HIV-1 Reverse Transcriptase Sequences from 382 Patients Recruited in JJ Hospital of Mumbai, India, between 2002 and 2008 / Alaka Deshpande / Aids Research and Human Retroviruses - June 2009 / 25 / 6
Detection of Drug Resistance-Associated and Background Mutations in Human Immunodeficiency Virus Type 1 CRF01_AE Protease and Reverse Transcriptase Derived from Drug Treatment-Naive Patients Residing in Central Thailand / Wattana Auwanit / Aids Research and Human Retroviruses - June 2009 / 25 / 6
Human Immunodeficiency Virus Type 1 gp 41 Mutations in Proviral DNA among Antiretroviral Treatment-Naive Individuals from India / Sourav Sen / Aids Research and Human Retroviruses - May 2009 / 25 / 5
A Novel Codon Insert in Protease of Clade B HIV Type 1 / Parris S. Jordan / Aids Research and Human Retroviruses - May 2009 / 25 / 5
Structural Basis of Drug Resistance by Genetic Variants of HIV Type 1 Clade C Protease from India / Abraham Joseph Kandathil / Aids Research and Human Retroviruses - May 2009 / 25 / 5
Low Prevalence of Drug Resistance Transmitted Virus in HIV Type 1-Infected ARV-Naive Patients in Cambodia / Janin Nouhin / Aids Research and Human Retroviruses - May 2009 / 25 / 5
HIV Type 1 Drug Resistance in Adults Receiving Highly Active Antiretroviral Therapy in Abidjan, Côte d'Ivoire / Debra L. Hanson / Aids Research and Human Retroviruses - May 2009 / 25 / 5
High HIV Type 1 Prevalence and Wide Genetic Diversity with Dominance of Recombinant Strains But Low Level of Antiretroviral Drug-Resistance Mutations in Untreated Patients in Northeast Gabon, Central Africa / Armel Mintsa-Ndong / Aids Research and Human Retroviruses - April 2009 / 25 / 4
HIV Type 1 Group M Subtype G in Cameroon: Five Genome Sequences / Julie Yamaguchi / Aids Research and Human Retroviruses - April 2009 / 25 / 4
First Detection of a Novel HIV Type 1 CRF01_AE/07_BC Recombinant among an Epidemiologically Linked Cohort of IDUs in Jiangsu, China / Hongxiong Guo / Aids Research and Human Retroviruses - April 2009 / 25 / 4
Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya. / Steegen K / AIDS Research and Therapy - June 2009 / 6 / 12
HIV-1 Resistance to First- and Second-Generation Non-nucleoside Reverse Transcriptase Inhibitors / Jade Ghosn / AIDS Reviews / 11 / 3
The Challenge of HIV-1 Antiretroviral Resistance in Africa in the Era of HAART / Hakim Sendagire / AIDS Reviews / 11 / 2
Characterization and Structural Analysis of HIV-1 Integrase Conservation / Francesca Ceccherini-Silberstein / AIDS Reviews / 11 / 1
HIV-1 Genotypic Drug Resistance Interpretation Rules – 2009 Spanish Guidelines / Carmen de Mendoza / AIDS Reviews / 11 / 1
Cohorts, trials, and evidence: expanding our confidence in guidelines for antiretroviral resistance testing. / Volberding P / Annals of Internal Medicine - July 2009 / 151 / 2
Natural Polymorphisms of HIV-1 Integrase and Inherent Susceptibilities to a Panel of Integrase Inhibitors. / Low A / Antimicrobial Agents and Chemotherapy - Epub ahead of print
Use of different inhibitory quotients to predict early virological response to Tipranavir in antiretroviral experienced HIV patients. / Morello J / Antimicrobial Agents and Chemotherapy - Epub ahead of print
Antiretroviral Drug Resistance Surveillance among Treatment-Naive Human Immunodeficiency Virus Type 1-Infected Individuals in Angola: Evidence for Low Level of Transmitted Drug Resistance / Inês Bártolo / Antimicrobial Agents and Chemotherapy - July 2009 / 53 / 7
Detection and Quantification of Minor Human Immunodeficiency Virus Type 1 Variants Harboring K103N and Y181C Resistance Mutations in Subtype A and D Isolates by Allele-Specific Real-Time PCR / Andrea Hauser / Antimicrobial Agents and Chemotherapy - July 2009 / 53 / 7
Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy / Constance Delaugerre / Antimicrobial Agents and Chemotherapy - July 2009 / 53 / 7
Treatment with the Fusion Inhibitor Enfuvirtide Influences the Appearance of Mutations in the Human Immunodeficiency Virus Type 1 Regulatory Protein Rev / Valentina Svicher / Antimicrobial Agents and Chemotherapy - July 2009 / 53 / 7
Predictive Value of Pharmacokinetics-Adjusted Phenotypic Susceptibility on Response to Ritonavir-Enhanced Protease Inhibitors (PIs) in Human Immunodeficiency Virus-Infected Subjects Failing Prior PI Therapy / Joseph J. Eron Jr / Antimicrobial Agents and Chemotherapy - June 2009 / 53 / 6
Susceptibility of Human Immunodeficiency Virus Type 1 to the Maturation Inhibitor Bevirimat Is Modulated by Baseline Polymorphisms in Gag Spacer Peptide 1 / Kurt Van Baelen / Antimicrobial Agents and Chemotherapy - May 2009 / 53 / 5
Human Immunodeficiency Virus Type 1 Isolates with the Reverse Transcriptase (RT) Mutation Q145M Retain Nucleoside and Nonnucleoside RT Inhibitor Susceptibility / Vici Varghese / Antimicrobial Agents and Chemotherapy - May 2009 / 53 / 5
Genotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from naïve and treated subjects. / Monno L / Antiviral Research - Epub ahead of print
Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda / Steven J Reynolds / Antiviral Therapy / 14 / 4
HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. / Orrell C / Antiviral Therapy / 14 / 4
In vivo selection by enfuvirtide of HIV type-1 env quasispecies with optimal potential for phenotypic expression of HR1 mutations. / Goubard A / Antiviral Therapy / 14 / 4
Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy / Simona Di Giambenedetto / Antiviral Therapy / 14
Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients / Alessandro Soria / Antiviral Therapy / 14
Historical resistance profile helps to predict salvage failure / Mauro Zaccarelli / Antiviral Therapy / 14
Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype / André Altmann / Antiviral Therapy / 14
Mutations in the thumb–connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients / Joshua M Waters / Antiviral Therapy / 14
Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment / Mattia CF Prosperi / Antiviral Therapy / 14
Immunological responses during a virologically failing antiretroviral regimen are associated with in vivo synonymous mutation rates of HIV type-1 env / Helene Mens / Antiviral Therapy / 14
Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries / Martine Peeters / Antiviral Therapy / 14
In vivo selection by enfuvirtide of HIV type-1 env quasispecies with optimal potential for phenotypic expression of HR1 mutations / Béatrice Labrosse / Antiviral Therapy / 14
HIV type-1 transmission dynamics in recent seroconverters: relationship with transmission of drug resistance and viral diversity / Patricia Recordon-Pinson / Antiviral Therapy / 14
A phylogenetic and Markov model approach for the reconstruction of mutational pathways of drug resistance. / Buendia P / Bioinformatics - Epub ahead of print
Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. / Johannessen A / BMC Infectious Diseases - July 2009 / 9 / 108
Characterization of the patterns of drug resistance mutations in newly diagnosed HIV-1 infected patients naive to the antiretroviral drugs. / Alteri C / BMC Infectious Diseases - July 2009 / 9 / 1
High Frequency of Clinically Significant Mutations after First-Line Generic Highly Active Antiretroviral Therapy Failure: Implications for Second-Line Options in Resource-Limited Settings / N. Kumarasamy / Clinical Infectious Diseases - July 2009 / 49 / 2
Antiretroviral Resistance Patterns and HIV-1 Subtype in Mother-Infant Pairs after the Administration of Combination Short-Course Zidovudine plus Single-Dose Nevirapine for the Prevention of Mother-to-Child Transmission of HIV / Amphan Chalermchockcharoenkit / Clinical Infectious Diseases - July 2009 / 49 / 2
High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. / Kumarasamv N / Clinical Infectious Diseases - July 2009 / 49 / 2
Replication Capacity of HIV-1 in the Presence of Resistance-Associated Substitutions in Protease / Dean L. Winslow / Clinical Infectious Diseases - July 2009 / 49 / 1
High Frequency of Antiretroviral Drug Resistance among HIV-Infected Adults Receiving First-Line Highly Active Antiretroviral Therapy in N’Djamena, Chad / Donato Koyalta / Clinical Infectious Diseases - July 2009 / 49 / 1
HIV-1 Superinfection in an HIV-2–Infected Woman with Subsequent Control of HIV-1 Plasma Viremia / Huldrych F. Günthard / Clinical Infectious Diseases - June 2009 / 48 / 11
Effect of HIV-1 Subtype on Virologic and Immunologic Response to Starting Highly Active Antiretroviral Therapy / Anna Maria Geretti / Clinical Infectious Diseases - May 2009 / 48 / 9
Are All Subtypes Created Equal? The Effectiveness of Antiretroviral Therapy against Non–Subtype B HIV-1 / Sergei L. Kosakovsky Pond / Clinical Infectious Diseases - May 2009 / 48 / 9
Low Levels of Antiretroviral-Resistant HIV Infection in a Routine Clinic in Cameroon that Uses the World Health Organization (WHO) Public Health Approach to Monitor Antiretroviral Treatment and Adequacy with the WHO Recommendation for Second-Line Treatment / Charles Kouanfack / Clinical Infectious Diseases - May 2009 / 48 / 9
Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients. / Saracine A / Current HIV Research - July 2009 / 7 / 4
Pre-screening HIV-1 reverse transcriptase resistance mutations in subtype B patients using a novel multiplex primer extension assay. / Jakobsen MR / Current HIV Research - July 2009 / 7 / 4
Management of paediatric HIV-1 resistance. / Gupta GB / Current Opinion Infectious Diseases - June 2009 / 22 / 3
Drug-resistant viruses may repair impaired fitness by mutations outside the drug target site. / Cai L / Future Microbiology - June 2009 / 4 / 507-9
Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial. / Hill A / HIV Medicine - Epub ahead of print
The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy / L Palmisano / HIV Medicine / 10 / 8
Primary drug resistance and transmission analysis of HIV-1 in acute and recent drug-naïve seroconverters in Singapore / CC Lee / HIV Medicine / 10 / 6
Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations / J Audsley / HIV Medicine / 10 / 4
Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India. / Kandathil AJ / Indian Journal of Medical Microbiology - July 2009 / 27 / 3
Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G. / Palma AC / Infections, Genetics and Evolution - Epub ahead of print
The frequency of HIV-I drug resistance mutations among treatment-naive individuals at a tertiary care centre in south India. / Kandathil AJ / International Journal of STD and AIDS - August 2009 / 20 / 8
Clinical and Genotypic Findings in HIV-Infected Patients With the K65R Mutation Failing First-Line Antiretroviral Therapy in Nigeria. / HawkinsCA / JAIDS - Epub ahead of print
Development of HIV-1 Drug Resistance Through 144 Weeks in Antiretroviral-Naïve Subjects on Emtricitabine, Tenofovir Disoproxil Fumarate, and Efavirenz Compared With Lamivudine/Zidovudine and Efavirenz in Study GS-01-934. / Margot NA / JAIDS - Epub ahead of print
Lower Risk of Resistance After Short-Course HAART Compared With Zidovudine/Single-Dose Nevirapine Used for Prevention of HIV-1 Mother-to-Child Transmission / Lehman, Dara / JAIDS - August 2009 / 51 / 5
Molecular Epidemiological Study of HIV-1 CRF01_AE Transmission in Hong Kong / Chen, J H K / JAIDS - August 2009 / 51 / 5
Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission. / Lehman DA / JAIDS - August 2009 / 51 / 5
Initiation of HAART at Higher CD4 Cell Counts Is Associated With a Lower Frequency of Antiretroviral Drug Resistance Mutations at Virologic Failure / Uy, Jonathan / JAIDS - August 2009 / 51 / 4
HIV-1 Genetic Diversity and Transmitted Drug Resistance in Health Care Settings in Maputo, Mozambique / Bártolo, Inês MSc / JAIDS - July 2009 / 51 / 3
Increased Detection of HIV-1 Drug Resistance at Time of Diagnosis by Testing Viral DNA With a Sensitive Assay / Ellis, Giovanina M / JAIDS - July 2009 / 51 / 3
104 A V3-independent pathway to resistance to small molecule CCR5 inhibitors / Anastasopoulou, Kleio / JAIDS - June 2009 / 51 / 2
Transmission Networks of Drug Resistance Acquired in Primary/Early Stage HIV Infection / BG, Brenner / JAIDS - June 2009 / 51 / 2
Survival of HIV-1 Infected Multidrug-Resistant Patients Recycling Enfuvirtide After a Previous Failure / Cossarini, Francesca / JAIDS - June 2009 / 51 / 2
HIV-1 Transmission Cluster With T215D Revertant Mutation Among Newly Diagnosed Patients From the Basque Country, Spain / Cuevas, Maria Teresa / JAIDS - May 2009 / 51 / 1
Lack of Primary Mutations Associated With Integrase Inhibitors Among HIV-1 Subtypes B, C, and F Circulating in Brazil / Passaes, Caroline Bittencourt / JAIDS - May 2009 / 51 / 1
Relationship of Injection Drug Use, Antiretroviral Therapy Resistance, and Genetic Diversity in the HIV-1 pol Gene / Kowalski, Jeanne / JAIDS - April 2009 / 50 / 4
Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors / Bracciale L / Journal of Antimicrobial Chemotherapy - Epub ahead of print
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. / Zazzi M / Journal of Antimicrobial Chemotherapy - Epub ahead of print
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance / Jean-Michel Molina / Journal of Antimicrobial Chemotherapy / 64 / 2
HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with virological failure to nucleoside drug combinations / César Garriga
/ Journal of Antimicrobial Chemotherapy / 64 / 2
Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen / Jade Ghosn / Journal of Antimicrobial Chemotherapy / 64 / 2
Using HIV resistance tests in clinical practice / Stephen Taylor / Journal of Antimicrobial Chemotherapy / 64 / 2
Evolution of raltegravir resistance during therapy / Nadine Sichtig / Journal of Antimicrobial Chemotherapy / 64 / 1
Rapid decline in the efficiency of HIV drug resistance genotyping from dried blood spots (DBS) and dried plasma spots (DPS) stored at 37°C and high humidity / J. Gerardo García-Lerma / Journal of Antimicrobial Chemotherapy / 64 / 1
Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort / Linda Wittkop / Journal of Antimicrobial Chemotherapy / 63 / 6